Cargando…

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA–chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinelli, M, Bonezzi, K, Riccardi, E, Kuhn, E, Frapolli, R, Zucchetti, M, Ryan, A J, Taraboletti, G, Giavazzi, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360417/ https://www.ncbi.nlm.nih.gov/pubmed/17848949 http://dx.doi.org/10.1038/sj.bjc.6603969

Ejemplares similares

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
por: McCarty, M F, et al.
Publicado: (2004)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
por: Alajez, Nehad M, et al.
Publicado: (2012)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012)

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
por: Ogata, A, et al.
Publicado: (2008)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response
por: Yang, Mu-qing, et al.
Publicado: (2018)

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells
por: Hamamura, R S, et al.
Publicado: (2007)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
por: Oflazoglu, E, et al.
Publicado: (2009)

An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen
por: Andersen, T T, et al.
Publicado: (2007)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo
por: Bannon, J H, et al.
Publicado: (2007)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology
por: Yin, Ting, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0npecto8si8dlu1jb37bslfrpg